AnaptysBio Profit Margin

AnaptysBio (ANAB) currently reports a profit margin of 82.37% as of June 2026. That compares with -107.66% in the prior-year period — up 176.5% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore AnaptysBio's profit margin history and peer comparisons.

AnaptysBio's profit margin increased from -107.66% to 82.37% — a 176.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AnaptysBio's profit margin of 82.37% is higher than the Healthcare sector average of 21.34%. That is roughly 286.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but AnaptysBio's current 82.37% should be judged against Healthcare norms (sector average: 21.34%) and against ANAB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 82.37%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for AnaptysBio, and consider following ANAB for alerts when major investors trade the stock.